EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CAR-T cell manufacturing: Major process parameters and next-generation strategies

Melanie Ayala Ceja iD, Mobina Khericha iD, Caitlin M Harris iD, Cristina Puig-Saus iD, Yvonne Y Chen iD

Journal of Experimental Medicine · 05.02.2024 · 221 (2)

DOI: 10.1084/jem.20230903 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Experimental Medicine, online erschienen am 16.01.2024. Verfasst von Melanie Ayala Ceja und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology, and Molecular Genetics, University of California-Los Angeles, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Autoimmune Diseases. Die Arbeit wurde bisher 322-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Parker Institute for Cancer Immunotherapy, California Institute for Regenerative Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoimmune diseases, is dependent on effective CAR-T cell manufacturing that impacts not only product safety and efficacy but also overall accessibility to patients in need. In this review, we discuss the major process parameters of autologous CAR-T cell manufacturing, as well as regulatory considerations and ongoing developments that will enable the next generation of CAR-T cell therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesHumansImmunotherapy, AdoptiveT-Lymphocytes

Autor:innen und Institutionen

  • Department of Microbiology, Immunology, and Molecular Genetics, University of California-Los Angeles, Los Angeles, CA, USA.
  • Department of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
  • Jonsson Comprehensive Cancer Center, University of California-Los Angeles , Los Angeles, CA, USA.
  • Parker Institute for Cancer Immunotherapy Center at University of California-Los Angeles , Los Angeles, CA, USA.
  • Department of Chemical and Biomolecular Engineering, University of California-Los Angeles, Los Angeles, CA, USA.

ORCID-Profile: Melanie Ayala Ceja, Mobina Khericha, Caitlin M Harris, Cristina Puig-Saus, Yvonne Y Chen

Förderung

  • NCI NIH HHS
  • Parker Institute for Cancer Immunotherapy
  • California Institute for Regenerative Medicine
  • Jean and Stephen Kaplan

Zitieren

APA

Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C., & Chen, Y. Y. (2024). CAR-T cell manufacturing: Major process parameters and next-generation strategies. Journal of Experimental Medicine, 221(2). https://doi.org/10.1084/jem.20230903

Vancouver

Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: Major process parameters and next-generation strategies. Journal of Experimental Medicine. 2024;221(2). doi:10.1084/jem.20230903

BibTeX
@article{AyalaCeja2024,
  author = {Ayala Ceja, Melanie and Khericha, Mobina and Harris, Caitlin M and Puig-Saus, Cristina and Chen, Yvonne Y},
  title = {CAR-T cell manufacturing: Major process parameters and next-generation strategies},
  journal = {Journal of Experimental Medicine},
  year = {2024},
  volume = {221},
  number = {2},
  doi = {10.1084/jem.20230903}
}
Kostenlos starten →